Adiponectin levels among patients with chronic hepatitis B and C infections and in response to IFN-α therapy

Liver International

Volumn 25, Issue 4, 2005, Pages 752-759

  Lu, Jin Ying ^a,b   Chuang, Lee Ming ^a   Yang, Wei Shiung ^a,b   Tai, Tong Yuan ^c   Lai, Ming Yang ^a,b   Chen, Pei Jer ^a,b   Kao, Jia Horng ^a,b   Lee, Cha Ze ^a   Lee, Hsuan Shu ^a  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^c NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

Author keywords

Adiponectin; Chronic hepatitis B; Chronic hepatitis C; IFN

Indexed keywords

ADIPONECTIN; ALANINE AMINOTRANSFERASE; ALPHA2B INTERFERON; ASPARTATE AMINOTRANSFERASE; C REACTIVE PROTEIN; GLUCOSE; HEMOGLOBIN A1C; HEPATITIS B(E) ANTIGEN; HEPATITIS C ANTIGEN; INSULIN; MESSENGER RNA; VIRUS DNA; VIRUS RNA;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ADULT; AGE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BODY MASS; CLINICAL ARTICLE; CONTROLLED STUDY; DIET RESTRICTION; DOWN REGULATION; FEMALE; GENDER; GLUCOSE BLOOD LEVEL; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN TISSUE; IMMUNE RESPONSE; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; MALE; PROTEIN BLOOD LEVEL; STEADY STATE; STUDENT T TEST;

EID: 84984558810     PISSN: 14783223     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1478-3231.2005.1007.x     Document Type: Article

References (37)

1. Petrides A S. Liver disease and diabetes mellitus. Diabetes Rev 1994; 2: 2-18.
2. Custro N, Carroccio A, Ganci A, Scafidi V, Campagna P, Prima Di L, Montalto G. Glucose homeostasis in chronic viral hepatitis and liver cirrhosis. Diabetes Metab 2001; 27: 476-81.
3. Mason A L, Lau J Y N, Hoang N, et al. Association of diabetes mellitus and chronic hepatitis C virus infection. Hepatology 1999; 29: 328-33.
4. Mehta S H, Brancati F L, Sulkowski M S, Strathdee S A, Szklo M, Thomas D L. Prevalence of type 2 diabetes mellitus among persons with hepatitis C virus infection in the United States. Ann Intern Med 2000; 133: 592-99.
5. Moriyama M, Komine F, Shiota A. Response of liver histology to IFN therapy with chronic hepatitis B and C. Acta Hepatol Jpn 1993; 34: 375-84.
6. Poynard T, Leroy V, Cohard M, Thevenot T, Mathurin P, Opolon P, Zarski J P. Meta-analysis of IFN randomized trials in the treatment of viral hepatitis C: effects of dose and duration. Hepatology 1996; 24: 778-89.
7. Hayata T, Nakano Y, Yoshizawa K, Sodeyama T, Kiyosawa K. Effects of IFN on intrahepatic human leukocyte antigens and lymphocytes subsets in patients with chronic hepatitis B and C. Hepatology 1991; 13: 1022-8.
8. Imano E, Kanda T, Ishigami Y, et al. IFN induces insulin resistance in patients with chronic active hepatitis. J Hepatol 1998; 28: 189-93.
9. Konrad T, Vicini P, Zeuzem S, et al. IFN-α improves glucose tolerance in diabetic and non-diabetic patients with HCV-induced liver disease. Exp Clin Endocrinol Diabetes 1999; 107: 343-9.
10. Funahashi T, Nakamura T, Shimomura I. Role of adipocytokines on the pathogenesis of atherosclerosis in visceral obesity. Intern Med 1999; 38: 202-6.
11. Yokota T, Oritani K, Takahashi I, et al. Adiponectin, a new member of the family of soluble defense collagens, negatively regulates the growth of myelomonocytic progenitors and the functions of macrophage. Blood 2000; 96: 1723-32.
12. Arita Y, Kihara S, Ouchi N, et al. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun 1999; 257: 79-83.
13. Hotta K, Funahashi T, Arita Y, et al. Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Arterioscler Thromb Vasc Biol 2000; 20: 1595-9.
14. Ouchi N, Kihara S, Arita Y, et al. Novel modulator for endothelial adhesion molecules: adipocytes-derived plasma protein adiponectin. Circulation 1999; 100: 2473-6.
15. Comuzzie A G, Funahashi T, Sonnenberg G, et al. The genetic basis of plasma variation in adiponectin, a global endophenotype for obesity and metabolic syndrome. J Clin Endocrinol Metab 2001; 86: 4321-5.
16. Tietge U J F, Boker K H W, Manns M P, Bahr M J. Elevated circulating adiponectin levels in liver cirrhosis are associated with reduced liver function and hepatic hemodynamics. Am J Physiol Endocrinol Metab 2004; 287: E82-9.
17. Pei D, Jones C N O, Bhargava R, Chen I D I, Reaven G M. Evaluation of octreotide to assess insulin-mediated glucose disposal by the insulin suppression test. Diabetologia 1994; 37: 843-5.
18. Mattews D R, Hosker J P, Rudenski A S, Naylor B A, Treacher D F, Turner R C. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412-9.
19. Younossi Z M, Braun W E, Protiva D A, Gifford R W J, Straffon R A. Chronic viral hepatitis in renal transplant recipients with allografts functioning for more than 20 years. Transplantation 1999; 67: 272-5.
20. Gao B, Hong F, Radaeva S. Host factors and failure of interferon-α treatment in hepatitis C virus. Hepatology 2004; 39: 880-90.
21. Tai T Y, Lu J Y, Chen C L, Lai M Y, Chen P J, Kao J H, Lee C Z, Lee H S, Chuang L M, Jeng Y M. Interferon-α reduces insulin resistance and β-cell secretion in responders among patients with chronic hepatitis B and C. J Endocrinol 2003; 178: 457-65.
22. Hu K Q, Viering J M, Redeker A G. Viral, host and IFN-related factors modulating the effect of IFN therapy for hepatitis C virus infection. J Viral Hepatitis 2001; 8: 1-18.
23. Cerny A, Chisari F V. Pathogenesis of chronic hepatitis C, immunological features of hepatic injury and viral persistence. Hepatology 1999; 30: 595-601.
24. Foster G R. IFN in host defense. Semin Liver Dis 1997; 17: 287-94.
25. Pignatelli M, Waters J, Brown D. HLA class I antigens on the hepatocytes membrane during recovery from acute hepatitis B virus infection and during IFN therapy in chronic hepatitis B virus infection. Hepatology 1986; 6: 349-53.
26. Cervoni J P, Degos F, Marcellin P, Erlinger S. Acute hepatitis induced by α-IFN, associated with viral clearance, in chronic hepatitis C. J Hepatol 1997; 27: 1113-6.
27. Ouchi N, Kihara S, Arita Y, et al. Adiponectin, an adipocytes-derived protein, inhibits endothelia NF-κB signaling through a camp-dependent pathway. Circulation 2000; 102: 1296-301.
28. Fasshauer M, Klein J, Neumann S, Eszlinger M, Paschke R. Hormonal regulation of adiponectin gene expression in 3T3-L1 adipocytes. Biochem Biophys Res Commun 2002; 290: 1084-9.
29. Halleux C M, Takahashi M, Detry D R, Funahashi T, Matsuzawa Y, Brichard S M. Secretion of adiponectin and regulation of apM1 gene expression in human visceral adipose tissue. Biochem Biophys Res Commun 2001; 288: 1102-7.
30. Hotamisligil G S. The role of TNF alpha and TNF receptors in obesity and insulin resistance. J Intern Med 1999; 245: 621-5.
31. Larrea E, Garcia N, Qian C, Ceveira M P, Prieto J. Tumor necrosis factor α gene expression and the response to IFN in chronic hepatitis C. Hepatology 1996; 23: 210-7.
32. Kimball P, Elswick R K, Shiffman M. Ethnicity and cytokine production gauge response of patients with hepatitis C to IFN-α therapy. J Med Virol 2001; 65: 510-6.
33. Stark G R, Kerr I M, Williams B R G, Silverman R H, Schreiber R D. How cells respond to IFN. Annu Rev Biochem 1998; 67: 227-64.
34. Yamauchi T, Kamon J, Waki H, et al. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nature Med 2001; 7: 941-6.
35. Yang W S, Lee W J, Funahashi T, et al. Weight reduction increases plasma levels of an adipose-derived anti-inflammatory protein, adiponectin. J Clin Endocrinol Metabol 2001; 86: 3815-9.
36. Yang W S, Jeng C Y, Wu T J, et al. Synthetic peroxisome proliferator-activated receptor-γ agonist, rosiglitazone, increases plasma levels of adiponectin in type 2 diabetic patients. Diabetes Care 2002; 25: 376-80.
37. Weyer C, Funahashi T, Tanaka S, et al. Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab 2001; 86: 1930-5.